Abstract 2009 breast cancer symposium
Peripheral neuropathy grades 2—4, either sensory or motor was the most common nonhematologic toxicity seen in the trial, according to Dr. With the presentation of the results of the ADEBAR study, the authors suggested that EC-Doc provides a feasible and effective alternative option to dose-intensified FEC with a different safety profile in a high-risk breast cancer cohort abstract The data for overall survival were mentioned as immature. The first line trials included lapatinib with chemotherapy versus chemotherapy only or the combination of lapatinib plus AI versus AI alone. A prospective randomized study NNBC 3 finished recruitment of 4, patients last year comparing this test with clinico-pathologic risk factors. Discussant Dr.
News from the San Antonio Breast Cancer Symposium 2009
Previous AACR Meetings:
My opinion is different from this. So the high complication rate in reconstructive surgery after neoadjuvant chemotherapy plus bavacizumab is probably not only the result of the antigenetic effect of one agent but is much more the result of a wrong reconstructive technique in a wrong situation in suboptimally selected patients. However, there is a certain logistic effort in the routine clinical setting to obtain enough fresh tumor tissue for testing. An oral presentation compared different approaches for the statistical analysis of the BIG trial abstract The findings contrast with an earlier study in which women receiving paclitaxel-containing therapy without trastuzumab did have better outcomes if they developed peripheral neuropathy SABCS , abstract A
The I-SPY Trials
In both trials the combination showed significant better results in progression free survival PFS and clinical benefit rates, however, without significant influence on survival. Discussant Dr. Participants Dr.
In both trials the combination showed significant better results in progression free survival PFS and clinical benefit rates, however, without significant influence on survival. In addition the use of bevacizumab in triple negative disease might be of special interest. However, better predictors of ovarian status are required to avoid the stimulation of ovarian function by aromatase inhibitors many clinicians are afraid of. Androgen receptor AR expression in primary breast cancer BC : Correlations with clinical characteristics and outcomes. One presentation from a Dutch patient cohort concluded that the presence of micro-metastatic disease in the sentinel node is in itself not an indication for adjuvant systemic therapy since the prognosis was not affected by this finding abstract In a multivariate model, women were significantly more likely to develop peripheral neuropathy if they had treatment-associated hyperglycemia hazard ratio [HR], 1.